Timolol
Treatment for Glaucoma
Typical Dosage: One drop in affected eye(s) 1-2 times daily (0.25% or 0.5%)
Effectiveness
82%
Safety Score
70%
Clinical Trials
266
Participants
180K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
One drop in affected eye(s) 1-2 times daily (0.25% or 0.5%)
Time to Effect
30 minutes (maximal 1-2 hours)
Treatment Duration
Lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$240
Monitoring:$600
Side Effect Mgmt:$100
Total Annual:$940
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$1,253
Comparison vs Latanoprost
Cost Difference
$-100/year
Less expensive
QALY Difference
-0.10 QALYs
Worse outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$740
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$360/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$240/year
Potential OTC Price
$120/year
Estimated if OTC available
Early Treatment Benefit
+0.10 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATEMissed Diagnosis Risk
HIGHRequires Monitoring
YesNeeds lab work/checkups
Timolol Outcomes
for Glaucoma
Efficacy Outcomes
Overall Effectiveness
+82%
Response Rate
+75%
Common Side Effects
Ocular stinging/burning
+7%
Dry eyes
+3%
Bradycardia (slow heart rate)
+2%
Bronchospasm (in susceptible individuals)
+0.5%
Headache
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
17 completed trials for Timolol in Glaucoma
A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients
NCT00972426COMPLETEDPHASE4
32 participants
INTERVENTIONAL
Taipei, Taiwan
Started: Oct 1, 2009
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
NCT00823043COMPLETED
103 participants
OBSERVATIONAL
San Diego, United States
Started: Jan 1, 2009
Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
NCT00698945COMPLETEDPHASE4
40 participants
INTERVENTIONAL
Petaluma, United States
Started: Jun 1, 2008
Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy
NCT01779284COMPLETEDPHASE4
42 participants
INTERVENTIONAL
Thessaloniki, Greece
Started: Jan 1, 2012
Circadian Rhythms of Aqueous Humor Dynamics in Humans
NCT00572936COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Omaha, United States
Started: Mar 13, 2006
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
NCT00716859COMPLETEDPHASE3
139 participants
INTERVENTIONAL
Pembroke Pines, United States +47 more
Started: Jul 1, 2008
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
NCT06030193COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 13, 2025
COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
NCT00832377COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Started: Apr 24, 2009
24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
NCT00972257COMPLETEDPHASE4
64 participants
INTERVENTIONAL
Thessaloniki, Greece
Started: Jan 1, 2009
Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients
NCT02053298COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Leuven, Belgium
Started: Jan 1, 2014
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00804648COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Bourbonnais, United States +1 more
Started: Nov 1, 2008
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
NCT00824824COMPLETEDNA
21 participants
INTERVENTIONAL
Boston, United States
Started: Jan 1, 2009
Bimatoprost/Timolol Versus Travoprost/Timolol
NCT01542710COMPLETEDNA
80 participants
INTERVENTIONAL
Cairo, Egypt
Started: Jan 1, 2011
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
NCT03323164COMPLETEDPHASE4
35 participants
INTERVENTIONAL
Philadelphia, United States
Started: Jul 10, 2017
MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
NCT00449956COMPLETEDPHASE3
474 participants
INTERVENTIONAL
Started: Mar 12, 2007
A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT00751127COMPLETEDPHASE3
268 participants
INTERVENTIONAL
La Jolla, United States +16 more
Started: Jan 1, 1993
Absorption and Safety of Topical Timolol to Treat Chronic Wounds
NCT04903366COMPLETED
40 participants
OBSERVATIONAL
Mather, United States
Started: Nov 21, 2017
Showing 20 of 268 total trials